Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade

A minority of patients currently respond to single-agent immune-checkpoint blockade (ICB), and strategies to increase response rates are urgently needed. AXL is a receptor tyrosine kinase commonly associated with drug resistance and poor prognosis in many cancer types, including in clear-cell renal...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2021-12, Vol.27 (24), p.6749-6760
Hauptverfasser:	Terry, Stéphane, Dalban, Cécile, Rioux-Leclercq, Nathalie, Adam, Julien, Meylan, Maxime, Buart, Stéphanie, Bougoüin, Antoine, Lespagnol, Alexandra, Dugay, Frédéric, Moreno, Irelka Colina, Lacroix, Guillaume, Lorens, James B, Gausdal, Gro, Fridman, Wolf H, Mami-Chouaib, Fathia, Chaput, Nathalie, Beuselinck, Benoit, Chabaud, Sylvie, Barros-Monteiro, Janice, Vano, Yann, Escudier, Bernard, Sautès-Fridman, Catherine, Albiges, Laurence, Chouaib, Salem
Format:	Artikel
Sprache:	eng
Schlagworte:	B7-H1 Antigen - genetics B7-H1 Antigen - metabolism Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - pathology Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - genetics Kidney Neoplasms - pathology Life Sciences Nivolumab - therapeutic use Programmed Cell Death 1 Receptor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!